The factors influencing clinical outcomes after leukapheresis in acute leukaemia
Abstract Leukapheresis is used for the mechanical removal of leukaemic cells in hyperleukocytosis. However, the effectiveness of leukapheresis remains unclear due to selection and confounding factors in the cohorts. We compared the effectiveness of leukapheresis among the subgroups according to eith...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9c06f37174724cd5a9469db5bc02ff35 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9c06f37174724cd5a9469db5bc02ff35 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9c06f37174724cd5a9469db5bc02ff352021-12-02T11:39:39ZThe factors influencing clinical outcomes after leukapheresis in acute leukaemia10.1038/s41598-021-85918-82045-2322https://doaj.org/article/9c06f37174724cd5a9469db5bc02ff352021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85918-8https://doaj.org/toc/2045-2322Abstract Leukapheresis is used for the mechanical removal of leukaemic cells in hyperleukocytosis. However, the effectiveness of leukapheresis remains unclear due to selection and confounding factors in the cohorts. We compared the effectiveness of leukapheresis among the subgroups according to either the 2016 World Health Organization classification or the number of cytogenetic abnormalities with a retrospective, single-centre study from January 2009 to December 2018. Acute myeloid leukaemia (AML, n = 212) and acute lymphoblastic leukaemia (ALL, n = 97) were included. The 30-day survival rates (95% confidence interval, 95% CI) for AML and ALL were 86.3% (81.6–90.9%) and 94.8% (90.3–99.2%), respectively. For AML, ‘primary AML with myelodysplasia-related changes’ and ‘AML with biallelic mutation of CEBPA’ showed better 30-day survival outcomes (P = 0.026) than the other subgroups. A higher platelet count after leukapheresis was associated with better 30-day survival in AML patients (P = 0.029). A decrease in blast percentage count after leukapheresis was associated with better 30-day survival in ALL patients (P = 0.034). Our study suggested that prophylactic platelet transfusion to raise the platelet count to 50 × 109/L or greater might improve clinical outcome in AML patients undergoing leukapheresis.Howon LeeSilvia ParkJae-Ho YoonByung-Sik ChoHee-Je KimSeok LeeDong-Wook KimNack-Gyun ChungBin ChoKyoung Bo KimJaeeun YooDong Wook JekarlHyojin ChaeJihyang LimMyungshin KimEun-Jee OhYonggoo KimNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Howon Lee Silvia Park Jae-Ho Yoon Byung-Sik Cho Hee-Je Kim Seok Lee Dong-Wook Kim Nack-Gyun Chung Bin Cho Kyoung Bo Kim Jaeeun Yoo Dong Wook Jekarl Hyojin Chae Jihyang Lim Myungshin Kim Eun-Jee Oh Yonggoo Kim The factors influencing clinical outcomes after leukapheresis in acute leukaemia |
| description |
Abstract Leukapheresis is used for the mechanical removal of leukaemic cells in hyperleukocytosis. However, the effectiveness of leukapheresis remains unclear due to selection and confounding factors in the cohorts. We compared the effectiveness of leukapheresis among the subgroups according to either the 2016 World Health Organization classification or the number of cytogenetic abnormalities with a retrospective, single-centre study from January 2009 to December 2018. Acute myeloid leukaemia (AML, n = 212) and acute lymphoblastic leukaemia (ALL, n = 97) were included. The 30-day survival rates (95% confidence interval, 95% CI) for AML and ALL were 86.3% (81.6–90.9%) and 94.8% (90.3–99.2%), respectively. For AML, ‘primary AML with myelodysplasia-related changes’ and ‘AML with biallelic mutation of CEBPA’ showed better 30-day survival outcomes (P = 0.026) than the other subgroups. A higher platelet count after leukapheresis was associated with better 30-day survival in AML patients (P = 0.029). A decrease in blast percentage count after leukapheresis was associated with better 30-day survival in ALL patients (P = 0.034). Our study suggested that prophylactic platelet transfusion to raise the platelet count to 50 × 109/L or greater might improve clinical outcome in AML patients undergoing leukapheresis. |
| format |
article |
| author |
Howon Lee Silvia Park Jae-Ho Yoon Byung-Sik Cho Hee-Je Kim Seok Lee Dong-Wook Kim Nack-Gyun Chung Bin Cho Kyoung Bo Kim Jaeeun Yoo Dong Wook Jekarl Hyojin Chae Jihyang Lim Myungshin Kim Eun-Jee Oh Yonggoo Kim |
| author_facet |
Howon Lee Silvia Park Jae-Ho Yoon Byung-Sik Cho Hee-Je Kim Seok Lee Dong-Wook Kim Nack-Gyun Chung Bin Cho Kyoung Bo Kim Jaeeun Yoo Dong Wook Jekarl Hyojin Chae Jihyang Lim Myungshin Kim Eun-Jee Oh Yonggoo Kim |
| author_sort |
Howon Lee |
| title |
The factors influencing clinical outcomes after leukapheresis in acute leukaemia |
| title_short |
The factors influencing clinical outcomes after leukapheresis in acute leukaemia |
| title_full |
The factors influencing clinical outcomes after leukapheresis in acute leukaemia |
| title_fullStr |
The factors influencing clinical outcomes after leukapheresis in acute leukaemia |
| title_full_unstemmed |
The factors influencing clinical outcomes after leukapheresis in acute leukaemia |
| title_sort |
factors influencing clinical outcomes after leukapheresis in acute leukaemia |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/9c06f37174724cd5a9469db5bc02ff35 |
| work_keys_str_mv |
AT howonlee thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT silviapark thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT jaehoyoon thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT byungsikcho thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT heejekim thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT seoklee thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT dongwookkim thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT nackgyunchung thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT bincho thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT kyoungbokim thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT jaeeunyoo thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT dongwookjekarl thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT hyojinchae thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT jihyanglim thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT myungshinkim thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT eunjeeoh thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT yonggookim thefactorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT howonlee factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT silviapark factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT jaehoyoon factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT byungsikcho factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT heejekim factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT seoklee factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT dongwookkim factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT nackgyunchung factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT bincho factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT kyoungbokim factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT jaeeunyoo factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT dongwookjekarl factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT hyojinchae factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT jihyanglim factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT myungshinkim factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT eunjeeoh factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia AT yonggookim factorsinfluencingclinicaloutcomesafterleukapheresisinacuteleukaemia |
| _version_ |
1718395715521085440 |